Andrew N Billin Selected Research

Ligands

2/2008	Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.
1/2008	Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.
1/2008	Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
12/2007	Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
11/2007	PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism.
5/2007	A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity.
4/2006	Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew N Billin Research Topics

Disease

7	Fibrosis (Cirrhosis) 01/2023 - 01/2019
7	Non-alcoholic Fatty Liver Disease 01/2023 - 01/2020
4	Neoplasms (Cancer) 01/2022 - 12/2007
4	Carcinogenesis 01/2008 - 04/2006
3	Sclerosing Cholangitis 01/2023 - 01/2019
3	Inflammation (Inflammations) 05/2008 - 11/2007
2	Pruritus (Itching) 01/2023 - 01/2020
2	Alcoholic Fatty Liver 01/2023 - 01/2022
2	Fatty Liver 01/2022 - 01/2020
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 01/2020
2	Dyslipidemias (Dyslipidemia) 10/2008 - 08/2007
2	Type 2 Diabetes Mellitus (MODY) 10/2008 - 08/2007
2	Colonic Neoplasms (Colon Cancer) 01/2008 - 04/2006
2	Polyps 12/2007 - 04/2006
1	Headache (Headaches) 01/2023
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2023
1	Disease Progression 12/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Rheumatoid Arthritis 01/2022
1	Cholestasis 01/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2019
1	Hypoxia (Hypoxemia) 11/2018
1	Sarcoma (Soft Tissue Sarcoma) 11/2014
1	Genetic Translocation (Chromosomal Translocation) 11/2014
1	Rhabdomyosarcoma 11/2014
1	Cardiac Arrhythmias (Arrythmia) 02/2010
1	Breast Neoplasms (Breast Cancer) 01/2008
1	Melanoma (Melanoma, Malignant) 01/2008
1	Obesity 01/2008
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2008
1	Colorectal Neoplasms (Colorectal Cancer) 01/2008
1	Insulin Resistance 12/2007
1	Colitis 11/2007
1	Body Weight (Weight, Body) 11/2007
1	Leukemia 05/2007

Drug/Important Bio-Agent (IBA)

8	PPAR-betaIBA 10/2008 - 04/2006
7	LigandsIBA 02/2008 - 04/2006
6	cilofexorIBA 01/2023 - 01/2019
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2020
4	Bile Acids and Salts (Bile Acids)IBA 12/2022 - 01/2019
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2008 - 04/2006
4	(4- (((2- (3- fluoro- 4- (trifluoromethyl)phenyl)- 4- methyl- 1,3- thiazol- 5- yl)methyl)sulfanyl)- 2- methylphenoxy)acetic acidIBA 01/2008 - 11/2007
2	firsocostatIBA 01/2023 - 01/2022
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2018 - 12/2007
2	GW 501516IBA 01/2008 - 12/2007
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2008 - 12/2007
2	PPAR gammaIBA 11/2007 - 08/2007
1	Triglycerides (Triacylglycerol)IBA 01/2023
1	oxidized low density lipoproteinIBA 01/2023
1	Acetyl-CoA CarboxylaseIBA 01/2023
1	Apolipoproteins B (ApoB)IBA 01/2023
1	Fenofibrate (CiL)FDA LinkGeneric 01/2023
1	Deoxycholic Acid (Sodium Deoxycholate)IBA 12/2022
1	Glycodeoxycholic AcidIBA 12/2022
1	16S Ribosomal RNAIBA 12/2022
1	Hydroxysteroid DehydrogenasesIBA 12/2022
1	AcidsIBA 12/2022
1	choloylglycine hydrolaseIBA 12/2022
1	Dehydrocholic Acid (Sodium Dehydrocholate)IBA 12/2022
1	tirabrutinibIBA 01/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022
1	semaglutideIBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 10/2021
1	Peptides (Polypeptides)IBA 10/2021
1	Interleukin-8 (Interleukin 8)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CollagenIBA 01/2021
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2020
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2019
1	Oxygen (Dioxygen)IBA 11/2018
1	DNA (Deoxyribonucleic Acid)IBA 11/2014
1	PotassiumIBA 02/2010
1	delta Opioid Receptors (delta Opioid Receptor)IBA 02/2008
1	ProstaglandinsIBA 01/2008
1	Prostaglandins EIBA 01/2008
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2008
1	AzoxymethaneIBA 01/2008
1	nimesulide (Aulin)IBA 01/2008
1	HDL CholesterolIBA 12/2007
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2007
1	Dextrans (Dextran)FDA Link 11/2007
1	Interferon-gamma (Interferon, gamma)IBA 11/2007
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 11/2007
1	Peroxidase (Myeloperoxidase)IBA 11/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2007
1	Interleukin-6 (Interleukin 6)IBA 11/2007
1	PPAR alphaIBA 08/2007
1	Retinoic Acid Receptor alphaIBA 05/2007
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2007
1	Cathepsin EIBA 04/2006

Therapy/Procedure

5	Therapeutics 01/2023 - 11/2014